Over a 2-year treatment period, patients on ALZ-801 demonstrated significant correlations between effects on volumetric MRI outcomes and 3 cognitive scales, suggesting cognitive gains are a result of preservation of brain structures from neurodegeneration and atrophy.
Several experts in neuroimmune disorders discuss the mechanisms of action that underlie these disorders, and how the perception of their pathology has changed. [WATCH TIME: 7 minutes]
Findings from a recent exploratory study suggest that assessing daily functioning in a more sensitive way may identify Alzheimer disease before a patient develops more pronounced cognitive changes.
The professor of neurology at the NYU Grossman School of Medicine discussed the RECOVER-NEURO trial that is focused on improving cognitive dysfunction in patients with long COVID symptoms. [WATCH TIME: 5 minutes]
The director of the Pediatric Epilepsy Center at UCSF provided perspective on STK-001, a promising antisense oligonucleotide in development, and the shift in how Dravet syndrome is discussed and managed.
Patients treated for more than 28 days had a higher chance of status epilepticus cessation, but also a high risk of moderate to severe disability at discharge.
One meta-analysis featuring 8 studies showed that more than half of patients reported a 100% reduction in their generalized tonic-clonic seizures or tonic-clonic seizures.
A group of panelists discussed the history of the Siegel Rare Neuroimmune Association, and the progress made on rare neuroimmune disorders in the nearly 30 years since its existence.
Episode 37 of the AUPN Leadership Minute features David G. Standaert, MD, PhD, of the University of Alabama at Birmingham; and Erica A. Schuyler, MD, of the University of Connecticut. [WATCH TIME: 5 minutes]
Patients who have 1 of 4 recently identified genetic variants are at 10 times the risk of developing progressive multifocal leukoencephalopathy depending on specific treatments for their condition.
The genetic epidemiologist at the University of Pennsylvania discussed a recent study that highlighted the importance of diverse samples in genetic research for Alzheimer disease in helping to uncover hidden genetic risk factors. [WATCH TIME: 2 minutes]
A recent systematic review showed that AQP4+NMOSD in patients with systemic lupus erythematosus can mimic neuropsychiatric manifestations, frequently occur after the onset of lupus or may predate, and necessitate indefinite treatment.
The combined preclinical and clinical data with neflamapimod suggest the therapy has potential to be the first disease-modifying treatment for dementia with Lewy Bodies, demonstrating a positive impact on cognition, function, and mobility.
Treatment with Nerivio did not differ from controls in outcomes of newborn weight, miscarriage rate, preterm birth rate, birth defect rate, stillbirths, and rate of newborns meeting developmental milestones 3 months postnatal.
The Rett Syndrome Behavior Questionnaire’s implementation as global outcome measure in FDA-approved trials was the result of its comprehensive nature since it includes behavior-related symptom questions as well as questions for regular behaviors.
The professor in the department of internal medicine at RUSH Medical College discussed a study aimed to provide insights to help tailor cognitive decline prevention programs and raise awareness about health disparities in minority populations. [WATCH TIME: 5 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
Recent research highlights how advanced technology like remote monitoring devices or wearables and smartphone-based apps for sleep health can be delivered at the point of care to meet the needs of patients.
The assistant professor at Hunter College discussed the importance of using a systematic approach to localization and thorough consideration of clinical symptoms to enhance diagnostic accuracy and reduce misdiagnosis in multiple sclerosis. [WATCH TIME: 4 minutes]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.
A composite analysis of motor skills, muscle strength, cognitive ability, daily living skills, and biomarker data showed statistically significant benefits with AMO-02.
Neurology News Network for the week ending September 9, 2023. [WATCH TIME: 3 minutes]
Researchers developed a novel “closed-loop” system that delivered electrical pulses in a brain region to synchronize brain activity recorded from another region in the brain to improve memory.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 8, 2023.
The associate professor of psychiatry at the University of Illinois at Chicago talked about the importance of diverse insight and perspectives from the headache community in shaping medical research priorities. [WATCH TIME: 3 minutes]
Antinuclear antibodies seem to be more associated with severe disease activity and poor prognosis among patients with NMOSD, which further implies that they may be potentially used as a prognostic marker for the disease.
The associate professor at Yeshiva University and Albert Einstein College of Medicine explored the challenge of discussing lifestyle changes for patients with migraine, noting that lifestyle modifications can be a valuable addition to migraine treatment. [WATCH TIME: 3 minutes]
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James Beck, PhD. [LISTEN TIME: 15 minutes]
Treatment with diazepam nasal spray resulted in a statistically significant change in time between seizure clusters, potentially reflecting a beneficial effect of intermittent rescue therapy.
Half of the treated individuals saw a reduction of more than 50% in the number and duration of epileptic spasms following treatment with CER-0001, a ketogenic therapy.
